206
Mahmoud et al.
Di Marzo V and Matias I (2005) Endocannabinoid control of food intake and energy
balance. Nat Neurosci 8:585–589.
Dormann D, Libotte T, Weijer CJ, and Bretschneider T (2002) Simultaneous quan-
tification of cell motility and protein-membrane-association using active contours.
Cell Motil Cytoskeleton 52:221–230.
Engeli S, Böhnke J, Feldpausch M, Gorzelniak K, Janke J, Bátkai S, Pacher P,
Harvey-White J, Luft FC, and Sharma AM et al. (2005) Activation of the peripheral
endocannabinoid system in human obesity. Diabetes 54:2838–2843.
Fay JF, Dunham TD, and Farrens DL (2005) Cysteine residues in the human
cannabinoid receptor: only C257 and C264 are required for a functional receptor,
and steric bulk at C386 impairs antagonist SR141716A binding. Biochemistry 44:
8757–8769.
Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, Bouaboula M,
Shire D, Le Fur G, and Casellas P (1995) Expression of central and peripheral
cannabinoid receptors in human immune tissues and leukocyte subpopulations.
Eur J Biochem 232:54–61.
McWhinney C, Wenham D, Kanwal S, Kalman V, Hansen C, and Robishaw JD (2000)
Constitutively active mutants of the alpha(1a)- and the alpha(1b)-adrenergic re-
ceptor subtypes reveal coupling to different signaling pathways and physiological
responses in rat cardiac myocytes. J Biol Chem 275:2087–2097.
Meschler JP, Kraichely DM, Wilken GH, and Howlett AC (2000) Inverse agonist
properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-
1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-
methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB
(1) cannabinoid receptor. Biochem Pharmacol 60:1315–1323.
Moreira FA and Crippa JA (2009) The psychiatric side-effects of rimonabant. Rev
Bras Psiquiatr 31:145–153.
Muccioli GG and Lambert DM (2005) Current knowledge on the antagonists and
inverse agonists of cannabinoid receptors. Curr Med Chem 12:1361–1394.
Pagotto U, Marsicano G, Cota D, Lutz B, and Pasquali R (2006) The emerging role of
the endocannabinoid system in endocrine regulation and energy balance. Endocr
Rev 27:73–100.
Gérard CM, Mollereau C, Vassart G, and Parmentier M (1991) Molecular cloning of
a human cannabinoid receptor which is also expressed in testis. Biochem J 279:
129–134.
Gether U and Kobilka BK (1998) G protein-coupled receptors. II. Mechanism of ag-
onist activation. J Biol Chem 273:17979–17982.
Ghanouni P, Steenhuis JJ, Farrens DL, and Kobilka BK (2001) Agonist-induced
conformational changes in the G-protein-coupling domain of the beta 2 adrenergic
receptor. Proc Natl Acad Sci USA 98:5997–6002.
Hildebrand PW, Scheerer P, Park JH, Choe HW, Piechnick R, Ernst OP, Hofmann
KP, and Heck M (2009) A ligand channel through the G protein coupled receptor
opsin. PLoS ONE 4:e4382.
Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I,
Teller DC, Okada T, and Stenkamp RE et al. (2000) Crystal structure of rhodopsin:
a G protein-coupled receptor. Science 289:739–745.
Park JH, Scheerer P, Hofmann KP, Choe HW, and Ernst OP (2008) Crystal structure
of the ligand-free G-protein-coupled receptor opsin. Nature 454:183–187.
Pei Y, Mercier RW, Anday JK, Thakur GA, Zvonok AM, Hurst D, Reggio PH, Janero
DR, and Makriyannis A (2008) Ligand-binding architecture of human CB2 can-
nabinoid receptor: evidence for receptor subtype-specific binding motif and mod-
eling GPCR activation. Chem Biol 15:1207–1219.
Pertwee RG (2005) Inverse agonism and neutral antagonism at cannabinoid CB1
receptors. Life Sci 76:1307–1324.
Howlett AC (1995) Pharmacology of cannabinoid receptors. Annu Rev Pharmacol
Toxicol 35:607–634.
Howlett AC (2005) Cannabinoid receptor signaling. Handb Exp Pharmacol 168:53–79.
Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, and Porrino LJ
(2004) Cannabinoid physiology and pharmacology: 30 years of progress. Neuro-
pharmacology 47 (Suppl 1):345–358.
Howlett AC and Fleming RM (1984) Cannabinoid inhibition of adenylate cyclase.
Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol
26:532–538.
Hurst D, Umejiego U, Lynch D, Seltzman H, Hyatt S, Roche M, McAllister S,
Fleischer D, Kapur A, and Abood M et al. (2006) Biarylpyrazole inverse agonists at
the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/
lysine3.28(192) interaction. J Med Chem 49:5969–5987.
Hurst DP, Grossfield A, Lynch DL, Feller S, Romo TD, Gawrisch K, Pitman MC,
and Reggio PH (2010) A lipid pathway for ligand binding is necessary for a cannabinoid
G protein-coupled receptor. J Biol Chem 285:17954–17964.
Hurst DP, Lynch DL, Barnett-Norris J, Hyatt SM, Seltzman HH, Zhong M, Song ZH,
Nie J, Lewis D, and Reggio PH (2002) N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-
dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction
with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 re-
ceptor. Mol Pharmacol 62:1274–1287.
Janero DR (2012) Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond
obesity and cardiometabolic disorders to substance abuse/drug addiction with
CB1R neutral antagonists. Expert Opin Emerg Drugs 17:17–29.
Janero DR and Makriyannis A (2009) Cannabinoid receptor antagonists: pharma-
cological opportunities, clinical experience, and translational prognosis. Expert
Opin Emerg Drugs 14:43–65.
Pertwee RG (2006) Cannabinoid pharmacology: the first 66 years. Br J Pharmacol
147 (Suppl 1):S163–S171.
Picone RP, Khanolkar AD, Xu W, Ayotte LA, Thakur GA, Hurst DP, Abood ME,
Reggio PH, Fournier DJ, and Makriyannis
A (2005) (-)-79-Isothiocyanato-11-
hydroxy-19,19-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electro-
philic ligand, interacts covalently with a cysteine in helix six and activates the CB1
cannabinoid receptor. Mol Pharmacol 68:1623–1635.
Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez
S, Maruani J, Néliat G, and Caput D et al. (1994) SR141716A, a potent and se-
lective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240–244.
Rinaldi-Carmona M, Barth F, Millan J, Derocq JM, Casellas P, Congy C, Oustric D,
Sarran M, Bouaboula M, and Calandra B et al. (1998a) SR 144528, the first potent
and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther
284:644–650.
Rinaldi-Carmona M, Le Duigou A, Oustric D, Barth F, Bouaboula M, Carayon P,
Casellas P, and Le Fur G (1998b) Modulation of CB1 cannabinoid receptor func-
tions after a long-term exposure to agonist or inverse agonist in the Chinese
hamster ovary cell expression system. J Pharmacol Exp Ther 287:1038–1047.
Rozenfeld R and Devi LA (2008) Regulation of CB1 cannabinoid receptor trafficking
by the adaptor protein AP-3. FASEB J 22:2311–2322.
Scheerer P, Park JH, Hildebrand PW, Kim YJ, Krauss N, Choe HW, Hofmann KP,
and Ernst OP (2008) Crystal structure of opsin in its G-protein-interacting con-
formation. Nature 455:497–502.
Shim JY, Bertalovitz AC, and Kendall DA (2012) Probing the interaction of
SR141716A with the CB1 receptor. J Biol Chem 287:38741–38754.
Silvestri C and Di Marzo V (2012) Second generation CB1 receptor blockers and other
inhibitors of peripheral endocannabinoid overactivity and the rationale of their use
against metabolic disorders. Expert Opin Investig Drugs 21:1309–1322.
Silvestri C, Ligresti A, and Di Marzo V (2011) Peripheral effects of the endocannabinoid
system in energy homeostasis: adipose tissue, liver and skeletal muscle. Rev Endocr
Metab Disord 12:153–162.
Jones D (2008) End of the line for cannabinoid receptor 1 as an anti-obesity target?
Nat Rev Drug Discov 7:961–962.
Kenakin T (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.
Trends Pharmacol Sci 16:232–238.
Landsman RS, Burkey TH, Consroe P, Roeske WR, and Yamamura HI (1997)
SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur J
Pharmacol 334:R1–R2.
Lange JH and Kruse CG (2005) Keynote review: medicinal chemistry strategies to
CB1 cannabinoid receptor antagonists. Drug Discov Today 10:693–702.
Lange JH and Kruse CG (2008) Cannabinoid CB1 receptor antagonists in therapeutic
and structural perspectives. Chem Rec 8:156–168.
Leterrier C, Bonnard D, Carrel D, Rossier J, and Lenkei Z (2004) Constitutive
endocytic cycle of the CB1 cannabinoid receptor. J Biol Chem 279:36013–36021.
Mackie K (2006) Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol
Toxicol 46:101–122.
Marcu J, Shore DM, Kapur A, Trznadel M, Makriyannis A, Reggio PH, and Abood
ME (2013) Novel insights into CB1 cannabinoid receptor signaling: a key in-
teraction identified between the extracellular-3 loop and transmembrane helix 2.
J Pharmacol Exp Ther 345:189–197.
Slipetz DM, O’Neill GP, Favreau L, Dufresne C, Gallant M, Gareau Y, Guay D,
Labelle M, and Metters KM (1995) Activation of the human peripheral cannabinoid
receptor results in inhibition of adenylyl cyclase. Mol Pharmacol 48:352–361.
Song ZH and Bonner TI (1996) A lysine residue of the cannabinoid receptor is critical
for receptor recognition by several agonists but not WIN55212-2. Mol Pharmacol
49:891–896.
Traynor K (2007) Panel advises against rimonabant approval. Am J Health Syst
Pharm 64:1460–1461.
Turu G and Hunyady L (2010) Signal transduction of the CB1 cannabinoid receptor.
J Mol Endocrinol 44:75–85.
Vemuri VK, Janero DR, and Makriyannis A (2008) Pharmacotherapeutic targeting of
the endocannabinoid signaling system: drugs for obesity and the metabolic syn-
drome. Physiol Behav 93:671–686.
Visiers I, Ebersole BJ, Dracheva S, Ballesteros J, Sealfon SC, and Weinstein H (2002)
Structural motifs as functional microdomains in G-protein-coupled receptors: en-
ergetic considerations in the mechanism of activation of the serotonin 5-HT2A re-
ceptor by disruption of the ionic lock of the arginine cage. Int J Quantum Chem 88:
65–75.
Marion S, Weiner DM, and Caron MG (2004) RNA editing induces variation in de-
sensitization and trafficking of 5-hydroxytryptamine 2c receptor isoforms. J Biol
Chem 279:2945–2954.
Martini L, Waldhoer M, Pusch M, Kharazia V, Fong J, Lee JH, Freissmuth C,
and Whistler JL (2007) Ligand-induced down-regulation of the cannabinoid 1 re-
ceptor is mediated by the G-protein-coupled receptor-associated sorting protein
GASP1. FASEB J 21:802–811.
McAllister SD, Hurst DP, Barnett-Norris J, Lynch D, Reggio PH, and Abood ME
(2004) Structural mimicry in class A G protein-coupled receptor rotamer toggle
switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid
CB1 receptor activation. J Biol Chem 279:48024–48037.
Wade SM, Lan K, Moore DJ, and Neubig RR (2001) Inverse agonist activity at the
alpha(2A)-adrenergic receptor. Mol Pharmacol 59:532–542.
Weïwer M, Bittker JA, Lewis TA, Shimada K, Yang WS, MacPherson L, Dandapani
S, Palmer M, Stockwell BR, and Schreiber SL et al. (2012) Development of small-
molecule probes that selectively kill cells induced to express mutant RAS. Bioorg
Med Chem Lett 22:1822–1826.
Address correspondence to: Debra A. Kendall, 69 N. Eagleville Rd.,
Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT
McAllister SD, Rizvi G, Anavi-Goffer S, Hurst DP, Barnett-Norris J, Lynch DL,
Reggio PH, and Abood ME (2003) An aromatic microdomain at the cannabinoid CB
(1) receptor constitutes an agonist/inverse agonist binding region. J Med Chem 46:
5139–5152.